Absci Corp. (($ABSI)) has held its Q4 earnings call. Read on for the main highlights of the call. Absci Corp’s recent earnings call presented a ...

Absci Corp (ABSI) showcases promising advancements in drug creation and secures additional funding, despite modest revenue growth and increased R&D expenses.

Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci ...

The company also announced a collaboration with chipmaker AMD to power its advanced de novo AI antibody design models, as well as AI biotechnology company Owkin to co-develop therapeutic candidates ...

As part of this partnership, AMD made a $20 million strategic investment in Absci. This collaboration supports our mission of creating better biologics faster by offering optimized compute ...

Entered into a strategic collaboration with AMD, including a $20 million investment, enhancing Absci's technological capabilities in AI drug discovery. Achieved 2024 outlook for drug creation ...

Ratings for Absci (NASDAQ:ABSI) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings ...

Absci Corporation (NASDAQ:ABSI) sells itself as an AI-integrated drug company. The stock is up significantly so far in 2025 as it announced a collaboration with AMD. This included a $20 million ...

In January 2025, Absci entered a strategic collaboration with AMD (NASDAQ:AMD), including a $20 million equity investment from the chip maker. The partnership aims to leverage AMD’s AI ...

and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ...

The company posted revenue of $0.7 million for Q4 2024, falling short of the $1.8 million consensus estimate. Adjusted earnings per share came in at -$0.25, $0.03 worse than analysts expected.

Absci Corporation (NASDAQ:ABSI) sells itself as an AI-integrated drug company. The stock is up significantly so far in 2025 as it announced a collaboration with AMD. This included a $20 million ...